Jan 19 | News
Astellas Pharma Europe Ltd, the European subsidiary of Tokyo-based Astellas Pharma Inc., has appointed Mike Crooks as General Manager of its UK affiliate, Astellas Pharma Ltd. (APL).
|
Jul 26 2011 | News
Merck, known as MSD outside the United States and Canada,
and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today
announced that they have entered into an agreement under which Merck, through a
subsidiary, will acquire the exclusive rights to develop and commercialize the investigational
intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico
and the United States
from Astellas.
|
Sep 21 2010 | News
Mylan Inc. said today it has received FDA approval for a generic version
of the Astellas Pharma
drug Prograf, which is used to prevent rejection of transplanted organs.
|
Jul 28 2010 | News
Regeneron Pharmaceuticals, Inc. and Astellas Pharma Inc. announced today that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product candidates.
|
Jul 20 2010 | News
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
|
Jun 8 2010 | News
Astellas Pharma Inc. announced today the completion of its tender offer for all outstanding shares of common stock in OSI Pharmaceuticals, Inc.
|
Mar 31 2010 | News
Astellas Pharma Inc. has extended its all-cash tender offer for $52 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals to 11:59 p.m. New York City time on Friday, April 23, 2010, unless further extended.
|
Mar 30 2010 | News
NEW YORK (AP) — Astellas Pharma Inc. said Monday it signed a confidentiality agreement with OSI Pharmaceuticals Inc., which has rejected Astellas's hostile $3.5 billion, or $52 per share, takeover offer as too low.
|
Mar 19 2010 | News
NEW YORK (AP) — Japanese drugmaker Astellas Pharma Inc. said Friday a federal antitrust waiting period expired in regard to its $3.5 billion takeover bid for OSI Pharmaceuticals Inc. expired.
|